Healthy Male ParticipantsHealthy volunteersDrugPhase 1
What this study is
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of P-glycoprotein (P-gp) substrate (dabigatran) in healthy male participants. This study will last approximately 21 days.
What's being tested
- Vimseltinib
Intervention · DRUG
- Dabigatran
Intervention · DRUG
Both interventions
Administered orally
Study details
- Official title
- A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Conditions
- Healthy Male Participants
- Enrolling
- 20 people
- Starts
- 2026-10-08
- Est. completion
- 2026-12
- Design
- Open-label, sequential groups, Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 55 YearsSex MALEHealthy volunteers AcceptedYou may qualify if
- Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
- Body mass index (BMI) from greater than or equal to (≥) 18 to less than or equal to ≤ 32 kilogram per square meter (kg/m^2).
- Adequate organ function and blood and urine tests, as required by the protocol and as determined by Principal Investigator.
You can't join if
- History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
- Unwilling or unable to comply with the requirements of the protocol.
- Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openDr. Vince Clinical Research
Overland Park, Kansas, United States
- Contact913-333-3000
- Benjamin T Sundling, D.O. · Principal investigator
Recruiting
Study team
Sponsor
Deciphera Pharmaceuticals, LLC
Study ID DCC-3014-01-009
Study director
Clinical Team
Deciphera Pharmaceuticals, LLC
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.